Skip to Main Content

Pfizer is making a major push to leverage mRNA technology, on which its Covid-19 vaccine is based, to develop new vaccines and treatments.

The drug giant said Monday it will pay Beam Therapeutics, a Cambridge, Mass., startup founded by Harvard researcher David Liu, $300 million to spend four years developing treatments for three undisclosed rare genetic diseases affecting the liver, the muscles, and the central nervous system.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

Create a display name to comment

This name will appear with your comment